期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 20, 期 20, 页码 5988-5993出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2010.08.091
关键词
Aurora-A; Selectivity; Kinases
资金
- NHS
- Cancer Research UK [CUK] [C309/A8274]
- Breakthrough Breast Cancer [AURA 05/06]
Co-crystallisation of the imidazo[ 1,2-a] pyrazine derivative 15 (3-chloro-N-(4-morpholinophenyl)-6-( pyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine) with Aurora-A provided an insight into the interactions of this class of compound with Aurora kinases. This led to the design and synthesis of potent Aurora-A inhibitors demonstrating up to 70-fold selectivity in cell-based Aurora kinase pharmacodynamic biomarker assays. (c) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据